ClinicalTrials.gg
CompletedNCT04711902Updated Oct 9, 2024Results posted

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

A Phase 3 interventional study of AIN457 and Secukinumab Placebo in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.

Enrollment
20th of 26
41 · median 231
Started
2021
with 2 others
Phase 3
16 of 26
1 open now
Registered
23rd of 26
by date
Lead sponsor
17 of 26
Novartis Pharmaceuticals

Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 20th largest by enrollment, is one of 3 that started in 2021, is one of 16 in phase 3, and was the 23rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing secukinumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.

Read the detailed description

This study used a randomized, double-blind, placebo-controlled, parallel-group design.

A screening period running up to 10 weeks before randomization was used to assess participant eligibility followed by 52 weeks of treatment.

A follow-up visit was done 12 weeks after last study treatment administration for all participants, regardless of whether they completed the entire study as planned or discontinued prematurely.

At Baseline, the patients fulfilling the inclusion criteria were randomized to one of the following two groups.

Group 1 : Secukinumab Dose level 1 s.c. at BSL, Week 1, 2, 3, 4, 8, and 12 Group 2 : Secukinumab Placebo s.c. at BSL, Week 1, 2, 3, 4, 8, and 12.

At Week 16, participants in Group 1 and Group 2 were to be re-randomized separately in a 1:1 ratio to receive secukinumab 150 mg or secukinumab 300 mg.

The duration of the entire treatment period was 52 weeks.

The primary objective was to demonstrate the treatment effect of secukinumab in Chinese subjects with active PsA by assessing American College of Rheumatology rresponse 20 (ACR20 response) rates at Week 16.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • PsA
  • immune-mediated chronic inflammatory disease
  • spondylarthritis
  • SpA
  • inflammatory musculoskeletal disease
  • China bridging study
  • AIN457
  • secukinumab
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated before any study assessment is performed.
  • Chinese male or non-pregnant, non-lactating Chinese female participants at least 18 years of age.
  • Diagnosis of PsA classified by Classification of Psoriatic Arthritis (CASPAR) criteria and with symptoms for at least 6 months with moderate to severe Psoriatic arthritis (PsA).
  • Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies negative at screening.
  • Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis or a documented history of plaque psoriasis.
  • Participants on Methotrexate (MTX) must be on folic acid supplementation at randomization.
  • Participants who are on a DMARD other than MTX must discontinue the DMARD 4 weeks prior to randomization visit except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine washout has been performed.

Exclusion criteria

Exclusion Criteria:

  • Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician
  • Participants taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine).
  • Previous exposure to secukinumab or other biologic drug directly targeting interleukin- 17 (IL-17) or IL-17 receptor
  • Participants who have ever received biologic immunomodulating agents except for those targeting Tumor necrosis factor alpha (TNFα).
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective during the entire study (during the entire study).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Arm 1

    Participants received 150 mg dose (dose level 1) of Secukinumab

    Drug: AIN457

  • Placebo comparator
    Arm 2

    Participants received Placebo of the study drug.

    Other: Secukinumab Placebo

  • Active comparator
    Arm 3

    Participants who received Placebo and switched to dose level 1 (150 mg) of secukinumab.

    Drug: AIN457 · Other: Secukinumab Placebo

  • Active comparator
    Arm 4

    Participants who received Placebo and switched to dose level 2 (300 mg) of secukinumab.

    Drug: AIN457 · Other: Secukinumab Placebo

Interventions

  • DrugAIN457

    Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

    Also known as: Secukinumab

  • OtherSecukinumab Placebo

    Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

06

What researchers measure

Primary outcomes

  1. ACR20 Response at Week 16

    Assessed the efficacy of secukinumab relative to placebo at week 16 using Non-responder imputation (NRI) and based on the percentage of participants achieving an ACR20 response (ACR = American College of Rheumatology). ACR20 response criteria is response ≥ 20% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (Visual Analog Scale (VAS)), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), and High-sensitivity C-reactive protein (hsCRP) or Erythrocyte sedimentation rate (ESR).

    Time frame: 16 weeks

Secondary outcomes

  1. ACR50 Response at Week 16

    To assess the effect of secukinumab versus placebo on the composite endpoint ACR50 response and based on the percentage of participants achieving an ACR50 response at Week 16 using NRI. ACR50 response criteria is response ≥ 50% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (VAS), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), HAQ-DI, and hsCRP or ESR.

    Time frame: 16 weeks

  2. Change From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16

    To assess the effect of secukinumab versus placebo on change from BSL in DAS28-CRP. The assessment is based on the reduction in DAS28-CRP score. The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR or CRP and the Patient Global Assessment of Disease Activity. The range of DAS28 score is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.

    Time frame: 16 weeks

  3. Change From Baseline in PASDAS Scores Using MMRM at Week 16

    To assess the the effect of secukinumab versus placebo on change from Baseline in PASDAS. Assessment was based on reduction in PASDAS score. PASDAS is a measure of disease activity based on Patient reported measures (excluding mental component score (MCS) of the medical outcomes survey Short Form-36 (SF-36-PCS)), skin, peripheral joint counts (Tender and Swollen joint counts), Dactylitis (LDI), Enthesitis (LEI), acute phase response (CRP) and Patient \& Physician global VAS scores. The range of PASDAS is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.

    Time frame: 16 weeks

  4. Change From Baseline in SF36-PCS Scores Using MMRM at Week 16

    To assess the effect of secukinumab versus placebo on change from Baseline in SF-36 PCS. The SF-36 is a widely used and extensively studied instrument to measure HRQoL among healthy participants and participants with acute and chronic conditions. Two overall summary scores, the Physical Component Score (PCS) and the Mental Component Score (MCS) also can be computed. SF36-PCS was used in this study. The range of SF36-PCS score is 0-100. Higher score means better health status. Negative change from baseline indicates a unfavorable outcome.

    Time frame: 16 weeks

  5. Change From Baseline in HAQ-DI Scores Using MMRM at Week 16

    To assess the effect of secukinumab versus placebo on change from Baseline in HAQ-DI. Assessment was based on improvement in HAQ-DI PCS scores. The HAQ-DI© is one of the most widely used measures to assess the long-term influence of chronic disease on a participant's level of functional ability and activity restriction, and calculated based on HAQ-DI questionnaire. There are 20 questions in eight categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The range of score is 0-3. Higher score means more severe disability. Negative change from baseline indicates a favorable outcome.

    Time frame: 16 weeks

07

Results

Posted Jul 19, 2024

Participant flow

In the 1st 16 weeks of study, the 41 participants enrolled were randomized to 2 groups: 1 group received secukinumab 150 mg \& the other received placebo. At week 16, the participants were re-randomized within each group for a total of 4 groups. Within the secukinumab group, 1 group continued to receive secukinumab 150 mg while the other half received secukinumab 300 mg. In the Placebo group, 1 group switched to secukinumab 150 mg while the other half switched to secukinumab 300 mg.

Treatment Period 1 (1st 16 Weeks)
Participant flow — Treatment Period 1 (1st 16 Weeks)
MilestoneSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)Secukinumab 150 mg to Secukinumab 150 mg (2nd Randomization)Secukinumab 150 mg to Secukinumab 300 mg (2nd Randomization)Placebo to Secukinumab 150 mg (2nd Randomization)Placebo to Secukinumab 300 mg (2nd Randomization)
Started20210000
Completed20210000
Not completed000000
Treatment Period 2 (From Week 16)
Participant flow — Treatment Period 2 (From Week 16)
MilestoneSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)Secukinumab 150 mg to Secukinumab 150 mg (2nd Randomization)Secukinumab 150 mg to Secukinumab 300 mg (2nd Randomization)Placebo to Secukinumab 150 mg (2nd Randomization)Placebo to Secukinumab 300 mg (2nd Randomization)
Started0010101011
Discont. from treatment before week 52000010
Completed study treatment001010911
Completed008101011
Not completed002000
Withdrew: Participant decision002000

Outcome measures

PrimaryACR20 Response at Week 16

Assessed the efficacy of secukinumab relative to placebo at week 16 using Non-responder imputation (NRI) and based on the percentage of participants achieving an ACR20 response (ACR = American College of Rheumatology). ACR20 response criteria is response ≥ 20% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (Visual Analog Scale (VAS)), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), and High-sensitivity C-reactive protein (hsCRP) or Erythrocyte sedimentation rate (ESR).

Time frame:
16 weeks
Reported as:
Count of participants · Participants
ACR20 Response at Week 16
ParticipantsSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)
ACR20 Response at Week 16146
Statistical analysis
  • Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2) · Regression, Logistic · Marginal difference: 39.91 · 95% CI 10.87 to 68.95
SecondaryACR50 Response at Week 16

To assess the effect of secukinumab versus placebo on the composite endpoint ACR50 response and based on the percentage of participants achieving an ACR50 response at Week 16 using NRI. ACR50 response criteria is response ≥ 50% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (VAS), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), HAQ-DI, and hsCRP or ESR.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
ACR50 Response at Week 16
ParticipantsSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)
ACR50 Response at Week 1631
Statistical analysis
  • Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2) · Regression, Logistic · Marginal difference: 11.86 · 95% CI -7.18 to 30.91
SecondaryChange From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16

To assess the effect of secukinumab versus placebo on change from BSL in DAS28-CRP. The assessment is based on the reduction in DAS28-CRP score. The DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR or CRP and the Patient Global Assessment of Disease Activity. The range of DAS28 score is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.

Time frame:
16 weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16
scores on a scaleSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)
Change From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16-1.47 ± 0.206-0.37 ± 0.200
Statistical analysis
  • Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2) · Mixed Models Analysis · Mixed model repeated measures (mmrm): -1.10 · 95% CI -1.68 to -0.52
SecondaryChange From Baseline in PASDAS Scores Using MMRM at Week 16

To assess the the effect of secukinumab versus placebo on change from Baseline in PASDAS. Assessment was based on reduction in PASDAS score. PASDAS is a measure of disease activity based on Patient reported measures (excluding mental component score (MCS) of the medical outcomes survey Short Form-36 (SF-36-PCS)), skin, peripheral joint counts (Tender and Swollen joint counts), Dactylitis (LDI), Enthesitis (LEI), acute phase response (CRP) and Patient \& Physician global VAS scores. The range of PASDAS is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.

Time frame:
16 weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline in PASDAS Scores Using MMRM at Week 16
scores on a scaleSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)
Change From Baseline in PASDAS Scores Using MMRM at Week 16-2.20 ± 0.245-0.55 ± 0.237
Statistical analysis
  • Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2) · Mixed Models Analysis · Mixed model repeated measures (mmrm): -1.65 · 95% CI -2.35 to -0.94
SecondaryChange From Baseline in SF36-PCS Scores Using MMRM at Week 16

To assess the effect of secukinumab versus placebo on change from Baseline in SF-36 PCS. The SF-36 is a widely used and extensively studied instrument to measure HRQoL among healthy participants and participants with acute and chronic conditions. Two overall summary scores, the Physical Component Score (PCS) and the Mental Component Score (MCS) also can be computed. SF36-PCS was used in this study. The range of SF36-PCS score is 0-100. Higher score means better health status. Negative change from baseline indicates a unfavorable outcome.

Time frame:
16 weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline in SF36-PCS Scores Using MMRM at Week 16
scores on a scaleSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)
Change From Baseline in SF36-PCS Scores Using MMRM at Week 164.28 ± 1.1540.08 ± 1.113
Statistical analysis
  • Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2) · Mixed Models Analysis · Mixed model repeated scores (mmrm): 4.20 · 95% CI 0.94 to 7.46
SecondaryChange From Baseline in HAQ-DI Scores Using MMRM at Week 16

To assess the effect of secukinumab versus placebo on change from Baseline in HAQ-DI. Assessment was based on improvement in HAQ-DI PCS scores. The HAQ-DI© is one of the most widely used measures to assess the long-term influence of chronic disease on a participant's level of functional ability and activity restriction, and calculated based on HAQ-DI questionnaire. There are 20 questions in eight categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The range of score is 0-3. Higher score means more severe disability. Negative change from baseline indicates a favorable outcome.

Time frame:
16 weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline in HAQ-DI Scores Using MMRM at Week 16
scores on a scaleSecukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)
Change From Baseline in HAQ-DI Scores Using MMRM at Week 16-0.31 ± 0.0650.09 ± 0.063
Statistical analysis
  • Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2) · Mixed Models Analysis · Mixed model repeated measures (mmrm): -0.40 · 95% CI -0.58 to -0.21

Adverse events

Collected over Adverse events were collected from first dose of study treatment to 30 days after last dose of study medication (on-treatment), up to approx. 52 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any AIN457 150 mg0/30 (0%)0/30 (0%)27/30 (90%)
Any AIN457 300 mg0/21 (0%)1/21 (4.8%)16/21 (76.2%)
Any AIN4570/41 (0%)1/41 (2.4%)37/41 (90.2%)
Placebo0/21 (0%)0/21 (0%)16/21 (76.2%)
Most frequent serious events
Most frequent serious events
EventAny AIN457 150 mgAny AIN457 300 mgAny AIN457Placebo
CataractEye disorders0/301/211/410/21
Epiretinal membraneEye disorders0/301/211/410/21
Most frequent other events
Showing 10 of 75
Most frequent other events
EventAny AIN457 150 mgAny AIN457 300 mgAny AIN457Placebo
HyperlipidaemiaMetabolism and nutrition disorders6/303/219/418/21
COVID-19Infections and infestations4/305/219/410/21
HyperuricaemiaMetabolism and nutrition disorders5/304/219/412/21
HypercholesterolaemiaMetabolism and nutrition disorders5/300/215/410/21
HypertensionVascular disorders4/300/214/411/21
Hepatic function abnormalHepatobiliary disorders3/302/215/410/21
Suspected COVID-19Infections and infestations3/302/215/410/21
Weight increasedInvestigations3/300/213/411/21
CoughRespiratory, thoracic and mediastinal disorders2/302/214/410/21
Alanine aminotransferase increasedInvestigations0/300/210/412/21

Baseline characteristics

Randomized set: All participants who were randomized.

Age, Continuous
Age, Continuous(years)Secukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)Total
Mean42.4 ± 9.7045.7 ± 10.4644.0 ± 10.11
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)Total
Female13518
Male71623
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 150 mg (Group 1)Placebo of Study Drug (Group 2)Total
Chinese202141
08

Study locations

12 sites
  • Novartis Investigative Site
    Chongqing, Chongqing 400010, China
  • Novartis Investigative Site
    Guang Zhou, Guang Dong Province 510120, China
  • Novartis Investigative Site
    Zhuzhou, Hunan 412000, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014010, China
  • Novartis Investigative Site
    Hohhot, Inner Mongolia 10050, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Pingxiang, Jiangxi 337000, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Shanghai, 200127, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jun 2022, 11 months.

Results were first posted in Jul 2024, 2 years 1 month after primary completion. A results delay was requested in Apr 2023.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 11 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2021
First posted
Jan 15, 2021
StartActual
Jun 24, 2021
Primary completionActual
Jun 2, 2022
CompletionActual
Mar 10, 2023
Results delay requested
Apr 26, 2023
Results first posted
Jul 19, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04711902
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Jun 24, 2021
Primary completion
Jun 2, 2022
Completion
Mar 10, 2023
Results posted
Jul 19, 2024
Last update
Oct 9, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion